Objectives
|
Situation A:Susceptibility test results are not available before starting the new treatment: |
Initial phase | Continuation phase | |||
Drugs |
Minimum duration in months |
Drugs | Duration in months | |
1 | Aminoglycoside | 3 | Ethionamide | 18 |
2 | Ethionamide | 3 | Ofloxacin | 18 |
3 | Pyrazinamide | 3 | ||
4 | Ofloxacin | 3 |
Situation B:Susceptibility test results are available before starting the new treatment: Resistance to isoniazid alone or in combination with resistance ot streptomycin(and/or with thiacetazone) Resistance to isoniazid and ethambutol with or without resistance ot streptomycin |
Resistance to | Initial phase | Continuation phase | ||
Drugs |
Minimum Duration in months |
Drugs |
Duration in months |
|
*Isoniazid (Streptomycin thiacetazone |
1.rifampicin 2.aminoglycoside 3.pyrazinamide 4.ethambutol |
2-3 2-3 2-3 2-3 |
1.rifampicin 2.ethambutol |
6 6 |
*Isoniazid and ethambutol (streptomycin) |
1.rifampicin 2.aminoglycoside 3.pyrazinamide 4.ethionamide |
3 3 3 3 |
1.rifampicin 2.ethionamide |
6 6 |
Acceptable third line regimens for the treatment of MDR TB |
Situation B:a.Susceptibility test results are available before starting the new treatment: Resistance to isoniazid and rifampiccin (with or without resistance to streptomycin) b. Resistance to isoniazid ,rifampicin,ethambutol(with or without resistance ot streptomycin)
|
Resistance to | Initial phase | Continuation phase | ||
Drugs |
Minimum duration in months |
Drugs |
Duration in months |
|
Isoniazid rifampicin and streptomycin |
1.aminoglycoside 2.ethionamide 3.pyrazinamide 4.ofloxacin 5.ethambutol |
3 3 3 3 3 |
1.ethionamide 2.ofloxacin 3.cycloserine |
18 18 18 |
Isoniazid rifampicin streptomycin and ethambutol |
1.aminoglycoside 2.ethionamide 3.pyrazinamide 4.ofloxacin 5.cycloserine |
3 3 3 3 |
1.ethionamide 2.ofloxacin 3.cycloserine |
18 18 18 |
Introduction | | | Criteria of MDR TB | | | Causes | | | Prevention | | | Management | | | Dosage and side effects |